Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide

Introduction: Plasma androgen receptor (AR) copy number (CN) status identifies castration-resistant prostate cancer (CRPC) patients with worse outcome on abiraterone/enzalutamide. However, the impact of AR CN changes on clinical outcome in CRPC is unknown. Materials and Methods: Plasma samples from...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Gurioli, Giorgia, Conteduca, Vincenza, Lolli, Cristian, Schepisi, Giuseppe, Gargiulo, Stefania, Altavilla, Amelia, Casadei, Chiara, Scarpi, Emanuela, De Giorgi, Ugo
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7542981/
https://ncbi.nlm.nih.gov/pubmed/33072600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.567809
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars